Last reviewed · How we verify
NCT07035613
Investigating Chinese Herbal Medicine for Modulating Gut Microbiota in Treating Inflammatory Bowel Disease: Molecular Mechanisms and Clinical Study
NA trial testing BXD treatment in IBD - Inflammatory Bowel Disease in 20 participants. Completed in 6 June 2025.
6 June 2025
Quick facts
| Lead sponsor | China Medical University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 27 February 2024 |
| Primary completion | 6 June 2025 |
| Estimated completion | 6 June 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- BXD treatment — full drug profile →
Conditions studied
- IBD - Inflammatory Bowel Disease — all drugs for IBD - Inflammatory Bowel Disease →
Sponsor
China Medical University Hospital
Who can join
20 and older, any sex, with IBD - Inflammatory Bowel Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this exploratory, single-arm intervention study is to evaluate whether Banxia Xiexin Decoction (BXD) can prevent colitis by modulating gut microbiota composition and regulating immune responses, including IgA production, in healthy adults. The main questions it aims to answer are: Can BXD prevent colitis by modulating gut microbiota composition? Can BXD enhance immune markers such as IgA without adverse effects? There is no comparison group in this study. Participants will: Take BXD daily for 14 days. Provide stool and blood samples for microbiota analysis and immune marker testing. Eligible participants include healthy men and women aged 20 years or older, with no major illnesses, autoimmune diseases, cancer, or recent use of antibiotics, immunosuppressants, or probiotics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07035613
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IBD - Inflammatory Bowel Disease
Currently open trials in the same condition.
- NCT07385807 — Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Out · recruiting
- NCT07444060 — Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease · recruiting
- NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
- NCT07230262 — Trial Comparing Multiport RObotic and Laparoscopic Surgery for Elective Colorectal Resections in IBD Patients (ACRO-IBD) · NA · recruiting
- NCT06993272 — Relaxation Music for Chronic Pain · NA · active not recruiting
Other China Medical University Hospital trials
Trials by the same sponsor.
- NCT07525700 — The Effects of Combining Electronic Picture Books With RPG-Based Gamified Learning on Nursing Students' Motivation and L · NA · not yet recruiting
- NCT07463391 — Chinese Classics Recitation Training in Subjective Cognitive Decline · NA · not yet recruiting
- NCT07482189 — Effectiveness and Efficiency of an Upper Limb Active-Passive Exoskeleton Robot in Patients With Frozen Shoulder · NA · not yet recruiting
- NCT07437144 — Exploring the Effects of Shangshou Daoyin Method on Improving Sleep Quality, Quality of Life, and TCM Constitution in Br · NA · not yet recruiting
- NCT07232667 — Digital Technology for Active and Healthy Ageing in Taiwan · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07035613 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China Medical University Hospital
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07035613.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing